<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102970</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.324</org_study_id>
    <secondary_id>DR-2016-269</secondary_id>
    <nct_id>NCT03102970</nct_id>
  </id_info>
  <brief_title>Pain Assessment in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.</brief_title>
  <acronym>MorphoCOPD1b</acronym>
  <official_title>Morpho-COPD1b : Pain Assessment in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of chronic obstructive pulmonary disease (COPD) is between 8 and 12% of the&#xD;
      adult population. This prevalence is expected to increase over the coming decades due to the&#xD;
      aging of the population and the continued exposure to risk factors for the disease. The&#xD;
      evolution of COPD is marked by the occurrence of exacerbations of varying severity and&#xD;
      patients are frequently admitted to the emergency department for evaluation, treatment and /&#xD;
      or hospitalization. Admission in emergency department for COPD exacerbation represents&#xD;
      approximately 1% of emergency admission.&#xD;
&#xD;
      Chronic pain is common in patients with Chronic Obstructive Pulmonary Disease (COPD). The&#xD;
      pain intensity may increase during acute episodes of exacerbations. This study is aimed to&#xD;
      compare pain intensity during exacerbation and stable phase of patients with chronic&#xD;
      obstructive pulmonary disease (COPD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pain is common in patients with Chronic Obstructive pulmonary Disease (COPD). The&#xD;
      pain intensity may increase during acute episodes of exacerbation. Fifty (50) patients in&#xD;
      acute exacerbation of COPD will be included in the emergency department of CHU Grenoble Alpes&#xD;
      and Hôpital du Sacré Coeur de Montréal. The intensity and characteristics of pain will be&#xD;
      evaluated from the Short-Form McGill Pain Questionnaire (SF-MPQ) and the Brief Pain Inventory&#xD;
      (BPI). Assessment of respiratory status, anxiety and depression, and clinical and biological&#xD;
      data, defining the severity of exacerbation, will also be collected. A 30-day follow-up&#xD;
      visit, after a return to the stable state of COPD, allowed the realization of Respiratory&#xD;
      Functional Exploration and the same questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">April 5, 2018</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of the short-form McGill Pain Questionnaire (SF-MPQ) between the exacerbation and the stable phase at 30 days</measure>
    <time_frame>30 days after exacerbation</time_frame>
    <description>McGill Pain Questionnaire (SF-MPQ)</description>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to emergency department for acute episodes of exacerbation of chronic&#xD;
        obstructive pulmonary disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 40 years&#xD;
&#xD;
          -  smoking at least ≥ 10 pack years&#xD;
&#xD;
          -  previous FEV / FVC &lt;0.70 post bronchodilator&#xD;
&#xD;
          -  admitted for exacerbations (GOLD definition)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A dementia or non-communicating patient&#xD;
&#xD;
          -  Patient with chronic pain of neoplastic origin or severe trauma (fracture ,&#xD;
             dislocation or severe pain) within 15 days before the date of inclusion&#xD;
&#xD;
          -  Patient with no social security insurance , with restricted liberty or under legal&#xD;
             protection&#xD;
&#xD;
          -  Pregnant woman parturient or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime MAIGNAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emergency department of Hôpital du Sacré Coeur de Montréal</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Department of university hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, Pain, Exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

